Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
*Leonurus artemisia* extract (LaE), derived from Chinese motherwort (also known as *Leonurus japonicus* or YiMuCao), is a botanical extract investigated for its anti-proliferative and pro-apoptotic effects in oncology, particularly bladder cancer. In vitro studies demonstrate that LaE inhibits the proliferation of human bladder cancer cells (such as BFTC-905) by inducing G1/G0 phase cell cycle arrest and triggering apoptosis. Its mechanism of action involves the activation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway and the induction of reactive oxygen species (ROS) production. Historically used in traditional medicine for gynecological and obstetrical conditions, recent research focuses on its potential as a therapeutic agent for various malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on leonurus artemisia extract.